Published in N Engl J Med on October 15, 1992
Caffeinated energy drinks--a growing problem. Drug Alcohol Depend (2008) 4.98
Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol (2006) 2.23
Caffeine use in children: what we know, what we have left to learn, and why we should worry. Neurosci Biobehav Rev (2009) 1.87
A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl) (2004) 1.81
Toxicant-induced loss of tolerance--an emerging theory of disease? Environ Health Perspect (1997) 1.66
Central and peripheral effects of sustained caffeine use: tolerance is incomplete. Br J Clin Pharmacol (2002) 0.91
High dietary caffeine consumption is associated with a modest increase in headache prevalence: results from the Head-HUNT Study. J Headache Pain (2009) 0.89
Caffeine Use Disorder: A Comprehensive Review and Research Agenda. J Caffeine Res (2013) 0.89
Headache disorders: differentiating and managing the common subtypes. Br J Pain (2012) 0.88
Sustained attention performance during sleep deprivation associates with instability in behavior and physiologic measures at baseline. Sleep (2014) 0.86
[Alimentary trigger factors that provoke migraine and tension-type headache]. Schmerz (2006) 0.84
Evaluating Dependence Criteria for Caffeine. J Caffeine Res (2011) 0.83
Caffeinated beverage and soda consumption and time to pregnancy. Epidemiology (2012) 0.81
Rapid development of tolerance to dipyridamole-associated headaches. Br J Clin Pharmacol (1999) 0.81
Water intake and post-exercise cognitive performance: an observational study of long-distance walkers and runners. Eur J Nutr (2012) 0.80
Eveningness Chronotype, Daytime Sleepiness, Caffeine Consumption, and Use of Other Stimulants Among Peruvian University Students. J Caffeine Res (2014) 0.80
Attentional bias for caffeine-related stimuli in high but not moderate or non-caffeine consumers. Psychopharmacology (Berl) (2005) 0.80
Clinical importance of caffeine withdrawal. N Engl J Med (1992) 0.79
The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology (Berl) (2014) 0.78
The assessment, diagnosis, and treatment of excessive sleepiness: practical considerations for the psychiatrist. Psychiatry (Edgmont) (2007) 0.78
Fourteen well-described caffeine withdrawal symptoms factor into three clusters. Psychopharmacology (Berl) (2008) 0.77
Caffeine dependence: fact or fiction? J R Soc Med (1995) 0.76
Coffee: grounds for concern? Proc (Bayl Univ Med Cent) (2015) 0.76
Acute caffeine effect on repeatedly measured P300. Environ Health Prev Med (2000) 0.75
No Enhancement of 24-Hour Visuomotor Skill Retention by Post-Practice Caffeine Administration. PLoS One (2015) 0.75
Chronic daily headaches. Ann Indian Acad Neurol (2012) 0.75
The airway effects of stopping regular oral theophylline in patients with asthma. Br J Clin Pharmacol (1998) 0.75
Primary Headache Disorders: Focus on Migraine. Rev Pain (2011) 0.75
Caffeine discontinuation improves acute migraine treatment: a prospective clinic-based study. J Headache Pain (2016) 0.75
Winning a won game: caffeine panacea for obesity syndemic. Curr Neuropharmacol (2010) 0.75
The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS (1988) 6.75
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med (2000) 6.65
Caffeine dependence syndrome. Evidence from case histories and experimental evaluations. JAMA (1994) 3.13
Transcriptional regulation during cardiac growth and development. Annu Rev Physiol (1993) 2.33
Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest (1997) 2.31
Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet (1993) 2.20
A conserved 28-base-pair element (HF-1) in the rat cardiac myosin light-chain-2 gene confers cardiac-specific and alpha-adrenergic-inducible expression in cultured neonatal rat myocardial cells. Mol Cell Biol (1991) 1.88
Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) (2001) 1.68
A ubiquitous factor (HF-1a) and a distinct muscle factor (HF-1b/MEF-2) form an E-box-independent pathway for cardiac muscle gene expression. Mol Cell Biol (1992) 1.61
Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn's disease. Eur J Gastroenterol Hepatol (2001) 1.60
Vertebrate tinman homologues XNkx2-3 and XNkx2-5 are required for heart formation in a functionally redundant manner. Development (1998) 1.58
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend (1995) 1.54
Viral sequences enable efficient and tissue-specific expression of transgenes in Xenopus. Nat Biotechnol (1998) 1.54
The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol (1993) 1.51
Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging (2002) 1.51
Presymptomatic diagnosis. A study in a country practice. J R Coll Gen Pract (1969) 1.48
Noninvasive imaging of the distribution in oxygen in tissue in vivo using near-infrared phosphors. Biophys J (1996) 1.48
Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer (1995) 1.47
In vitro chamber specification during embryonic stem cell cardiogenesis. Expression of the ventricular myosin light chain-2 gene is independent of heart tube formation. J Biol Chem (1993) 1.45
Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Br J Cancer (1999) 1.42
Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther (2001) 1.41
Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) (2001) 1.41
Osteoporosis screening in people with airways disease. Chron Respir Dis (2005) 1.41
Growing old: a country practice survey. J R Coll Gen Pract (1970) 1.40
Cigarette smoking and subjective response: effects of d-amphetamine. Clin Pharmacol Ther (1981) 1.33
Expired air carbon monoxide accumulation and elimination as a function of number of cigarettes smoked. Addict Behav (1980) 1.28
Facilitation of human tobacco self-administration by ethanol: a behavioral analysis. J Exp Anal Behav (1976) 1.26
The total number of neurons in the human neocortex unbiasedly estimated using optical disectors. J Microsc (1990) 1.26
Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend (1998) 1.25
Human cigarette smoking: effects of puff and inhalation parameters on smoke exposure. J Pharmacol Exp Ther (1987) 1.22
Comparison of progressive-ratio performance maintained by cocaine, methylphenidate and secobarbital. Psychopharmacologia (1975) 1.21
Human cigarette smoking: manipulation of number of puffs per bout, interbout interval and nicotine dose. J Pharmacol Exp Ther (1982) 1.20
Correlation between the light scattering and the mitochondrial content of normal tissues and transplantable rodent tumors. Anal Biochem (1995) 1.20
Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther (1990) 1.17
Progressive-ratio performance maintained by drug infusions: comparison of cocaine, diethylpropion, chlorphentermine, and fenfluramine. Psychopharmacology (Berl) (1978) 1.17
Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers. J Pharmacol Exp Ther (1999) 1.17
Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia, and gestation. Pediatr Res (1999) 1.17
Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend (1993) 1.15
Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend (1991) 1.14
Fluorocitrate inhibition of aconitate hydratase and the tricarboxylate carrier of rat liver mitochondria. Biochem J (1973) 1.13
Discriminative stimulus and subjective effects of smoked marijuana in humans. Psychopharmacology (Berl) (1988) 1.12
Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol (1997) 1.11
Improving measurement in clinical handover. Qual Saf Health Care (2009) 1.11
Low-dose caffeine discrimination in humans. J Pharmacol Exp Ther (1990) 1.11
Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology (Berl) (1996) 1.10
Discrete-trial choice procedure: effects of naloxone and methadone on choice between food and heroin. Pharmacol Rev (1975) 1.10
Gradual dose taper following chronic buprenorphine. Am J Addict (2001) 1.10
Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) (1999) 1.10
Caffeine tolerance and choice in humans. Psychopharmacology (Berl) (1992) 1.09
Radiotherapy of malignant nasal tumors in 67 dogs. J Am Vet Med Assoc (1987) 1.09
Effects of methadone on human cigarette smoking and subjective ratings. J Pharmacol Exp Ther (1984) 1.08
Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther (1996) 1.07
Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol (2001) 1.07
Hypoxia and VEGF mRNA expression in human tumors. Neoplasia (2002) 1.06
The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav (1997) 1.06
Diazepam use among methadone maintenance patients: patterns and dosages. Drug Alcohol Depend (1981) 1.05
Progressive ratio and fixed ratio schedules of cocaine-maintained responding in baboons. Psychopharmacology (Berl) (1979) 1.05
Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. Int J Radiat Oncol Biol Phys (2000) 1.05
Choice between food and heroin: effects of morphine, naloxone, and secobarbital. J Exp Anal Behav (1981) 1.05
Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability. J Pharmacol Exp Ther (1987) 1.05
Contingency management approaches to drug self-administration and drug abuse: efficacy and limitations. Addict Behav (1981) 1.05
Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. Eur J Pharmacol (1995) 1.04
Multiple binding sites for myogenic regulatory factors are required for expression of the acetylcholine receptor gamma-subunit gene. J Biol Chem (1991) 1.04
Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res (2001) 1.04
The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res (2001) 1.04
Low-dose caffeine physical dependence in humans. J Pharmacol Exp Ther (1990) 1.04
Biology of Isl1+ cardiac progenitor cells in development and disease. Cell Mol Life Sci (2007) 1.02
Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. J Exp Anal Behav (1992) 1.02
Caffeine withdrawal: a parametric analysis of caffeine dosing conditions. J Pharmacol Exp Ther (1999) 1.02
Allograft dermal implant (AlloDerm) in a previously irradiated field. Laryngoscope (2000) 1.01
Changes in Epstein-Barr virus antibody titers associated with aging. Proc Soc Exp Biol Med (1985) 1.00
Drug discrimination analysis of endogenous neuroactive steroids in rats. Eur J Pharmacol (1993) 1.00
Regulation of the tinman homologues in Xenopus embryos. Dev Biol (2000) 1.00
Human progressive-ratio performance: maintenance by pentobarbital. Psychopharmacology (Berl) (1983) 1.00
Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther (1995) 0.99
Effects of ethanol on cigarette smoking by volunteers without histories of alcoholism. Psychopharmacology (Berl) (1984) 0.98
Intravenous self-injection of methcathinone in the baboon. Pharmacol Biochem Behav (1994) 0.98
Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology (Berl) (1987) 0.98
Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Br J Pharmacol (1995) 0.98
Preference for diazepam, but not buspirone, in moderate drinkers. Psychopharmacology (Berl) (1996) 0.98
No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type. Neurobiol Aging (1994) 0.97
Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo. J Pharmacol Exp Ther (1980) 0.96
Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J Pharmacol Exp Ther (1986) 0.96
Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res (1999) 0.96
Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J Pharmacol Exp Ther (1998) 0.96
Effects of bone marrow transplantation on the cardiovascular abnormalities in canine mucopolysaccharidosis VII. Bone Marrow Transplant (2000) 0.96
Effects of external beam radiation on the allograft dermal implant. Otolaryngol Head Neck Surg (2000) 0.96
Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ]. Cancer Res (2000) 0.96
Effects of caffeine on cigarette smoking and subjective response. Clin Pharmacol Ther (1983) 0.95
Reuse of a disposable dialyser for home dialysis. Med J Aust (1976) 0.95
Modulation of cellular immunity in medical students. J Behav Med (1986) 0.95
Association of microvascular leakage with induction of nitric oxide synthase: effects of nitric oxide synthase inhibitors in various organs. Eur J Pharmacol (1995) 0.93
The effects of d-amphetamine on intake of food and a sweet fluid containing cocaine. Pharmacol Biochem Behav (1999) 0.93
Evaluating the reinforcement value of clinic-based privileges through a multiple choice procedure. Drug Alcohol Depend (1995) 0.93
Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker. J Surg Oncol (1997) 0.93
Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry (1998) 0.93
Drug tasting may confound human drug discrimination studies. Psychopharmacology (Berl) (1996) 0.93
Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15-1788) after 7 days of diazepam. Science (1982) 0.92
Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology (Berl) (2001) 0.92